A method for efficient loading of ciprofloxacin hydrochloride in cationic solid lipid nanoparticles: Formulation and microbiological evaluation

Nanomaterials

Volumn 8, Issue 5, 2018, Pages

  Pignatello, Rosario ^a   Leonardi, Antonio ^a   Fuochi, Virginia ^a   Petronio, Giulio Petronio ^a   Greco, Antonio S ^a   Furneri, Pio Maria ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Antimicrobial activity; DDAB; Drug encapsulation; Positive charge; SLN; Triethylamine

Indexed keywords

EID: 85047668199     PISSN: None     EISSN: 20794991     Source Type: Journal    
DOI: 10.3390/nano8050304     Document Type: Article

References (53)

1. Gutiérrez-Castrellón, P.; Díaz-García, L.; De Colsa-Ranero, A.; Cuevas-Alpuche, J.; Jiménez-Escobar, I. Efficacy and safety of ciprofloxacin treatment in urinary tract infections (UTIs) in adults: A systematic review with meta-analysis. Gac. Med. Mexico 2015, 151, 210–228.
2. Connett, G.J.; Pike, K.C.; Legg, J.P.; Cathie, K.; Dewar, A.; Foote, K.; Harris, A.; Faust, S.N. Ciprofloxacin during upper respiratory tract infections to reduce Pseudomonas aeruginosa infection in paediatric cystic fibrosis: A pilot study. Ther. Adv. Respir. Dis. 2015, 9, 272–280. [CrossRef] [PubMed]
3. Al-Mahallawi, A.M.; Khowessah, O.M.; Shoukri, R.A. Enhanced non invasive trans-tympanic delivery of ciprofloxacin through encapsulation into nano-spanlastic vesicles: Fabrication, in-vitro characterization, and comparative ex-vivo permeation studies. Int. J. Pharm. 2017, 522, 157–164. [CrossRef] [PubMed]
4. Charoo, N.A.; Kohli, K.; Ali, A.; Anwer, A. Ophthalmic delivery of ciprofloxacin hydrochloride from different polymer formulations: In vitro and in vivo studies. Drug Dev. Ind. Pharm. 2003, 29, 215–221. [CrossRef] [PubMed]
5. Mishra, G.P.; Bagui, M.; Tamboli, V.; Mitra, A.K. Recent applications of liposomes in ophthalmic drug delivery. J. Drug Deliv. 2011, 2011, 863734. [CrossRef] [PubMed]
6. Sohail, M.; Khurshid, M.; Saleem, H.G.; Javed, H.; Khan, A.A. Characteristics and antibiotic resistance of urinary tract pathogens isolated from Punjab, Pakistan. Jundishapur J. Microbiol. 2015, 8, e19272. [CrossRef] [PubMed]
7. Mandras, N.; Tullio, V.; Furneri, P.M.; Roana, J.; Allizond, V.; Scalas, D.; Cuffini, A.M. Key Roles of Human Polymorphonuclear Cells and Ciprofloxacin in Lactobacillus Species Infection Control. Antimicrob. Agents Chemother. 2016, 60, 1638–1641. [CrossRef] [PubMed]
8. Fàbrega, A.; Madurga, S.; Giralt, E.; Vila, J. Mechanism of action of and resistance to quinolones. Microb. Biotechnol. 2009, 2, 40–61. [CrossRef] [PubMed]
9. Jacoby, G.A. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 2005, 41 (Suppl. 2), S120–S126. [CrossRef] [PubMed]
10. Forier, K.; Raemdonck, K.; De Smedt, S.C.; Demeester, J.; Coenye, T.; Braeckmans, K. Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J. Control. Release 2014, 190, 607–623. [CrossRef] [PubMed]
11. Kalhapure, R.S.; Suleman, N.; Mocktar, C.; Seedat, N.; Govender, T. Nanoengineered drug delivery systems for enhancing antibiotic therapy. J. Pharm. Sci. 2015, 104, 872–905. [CrossRef] [PubMed]
12. Pachuau, L. Recent developments in novel drug delivery systems for wound healing. Expert Opin. Drug Deliv. 2015, 12, 1895–1909. [CrossRef] [PubMed]
13. Furneri, P.M.; Fuochi, V.; Pignatello, R. Lipid-based nanosized Delivery Systems for fluoroquinolones: A review. Curr. Pharm. Des. 2017, 23, 6696–6704. [CrossRef] [PubMed]
14. Furneri, P.M.; Petronio, G.P.; Fuochi, V.; Cupri, S.; Pignatello, R. Nanosized devices as antibiotics and antifungals delivery: Past, news, and outlook. In Nanostructures for Drug Delivery. A Volume in Micro and Nano Technologies; Andronescu, E., Grumezescu, A.M., Eds.; Elsevier: Amsterdam, Netherlands, 2017; pp. 697–748, ISBN 978-0-323-46143-6.
15. Pignatello, R.; Fuochi, V.; Petronio, G.; Greco, A.S.; Furneri, P.M. Formulation and characterization of erythromycin–loaded Solid Lipid Nanoparticles. Biointerface Res. Appl. Chem. 2017, 7, 2145–2150.
16. Loxley, A. Solid Lipid Nanoparticles for the Delivery of Pharmaceutical Actives. Drug Deliv. Technol. 2009, 9 (Suppl. 8), 32.
17. Carbone, C.; Leonardi, A.; Cupri, S.; Puglisi, G.; Pignatello, R. Pharmaceutical and biomedical applications of lipid-based nanocarriers. Pharm. Pat. Anal. 2014, 3, 199–215. [CrossRef] [PubMed]
18. Silva, A.C.; Amaral, M.H.; Sousa Lobo, J.M.; Almeida, H. Applications of Solid Lipid Nanoparticles (SLN) and Nanostructured Lipid Carriers (NLC): State of the Art (Editorial). Curr. Pharm. Des. 2017. [CrossRef] [PubMed]
19. Garud, A.; Singh, D.; Garud, N. Solid Lipid Nanoparticles (SLN): Method, Characterization and Applications. Int. Curr. Pharm. J. 2012, 1, 9384–9393. [CrossRef]
20. Gokce, E.H.; Ozyazici, M.; Souto, E.B. Nanoparticulate strategies for effective delivery of poorly soluble therapeutics. Ther. Deliv. 2010, 1, 149–167. [CrossRef] [PubMed]
21. Mehnert, W.; Mader, K. Solid lipid nanoparticles-Production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47, 165–196. [CrossRef]
22. Carbone, C.; Cupri, S.; Leonardi, A.; Puglisi, G.; Pignatello, R. Lipid-based nanocarriers for drug delivery and targeting: A patent survey of methods of production and characterization. Pharm. Pat. Anal. 2013, 2, 665–677. [CrossRef] [PubMed]
23. Puglia, C.; Offerta, A.; Carbone, C.; Bonina, F.; Pignatello, R.; Puglisi, G. Lipid Nanocarriers (LNC) and their applications in ocular drug delivery. Curr. Med. Chem. 2015, 22, 1589–1602. [CrossRef] [PubMed]
24. Pignatello, R.; Carbone, C.; Puglia, C.; Offerta, A.; Bonina, F.P.; Puglisi, G. Ophthalmic applications of lipid-based drug nanocarriers: An update of research and patenting activity. Ther. Deliv. 2015, 6, 1297–1318. [CrossRef] [PubMed]
25. Jain, D.; Banerjee, R. Comparison of ciprofloxacin hydrochloride-loaded protein, lipid, and chitosan nanoparticles for drug delivery. J. Biomed. Mater. Res. Part B Appl. Biomater. 2007, 86, 105–112. [CrossRef] [PubMed]
26. Shah, M.; Agrawal, Y.K.; Garala, K.; Ramkishan, A. Solid Lipid Nanoparticles of a Water Soluble Drug, Ciprofloxacin Hydrochloride. Indian J. Pharm. Sci. 2012, 74, 434–442. [CrossRef] [PubMed]
27. Khattar, H.; Singh, S.; Murthy, R.S.R. Formulation and Characterization of Nano Lipid Carrier Dry Powder Inhaler Containing Ciprofloxacin Hydrochloride and N-Acetyl Cysteine. Int. J. Drug Deliv. 2012, 4, 316–325.
28. Shah, M.; Agrawal, Y. Ciprofloxacin hydrochloride-loaded glyceryl monostearate nanoparticle: Factorial design of Lutrol F68 and Phospholipon 90G. J. Microencapsul. 2012, 29, 331–343. [CrossRef] [PubMed]
29. Shah, M.; Agrawal, Y. Development of ciprofloxacin HCl-based Solid Lipid Nanoparticles using Ouzo Effect: An experimental optimization and comparative study. J. Dispers. Sci. Technol. 2013, 34, 37–46. [CrossRef]
30. Gandomi, N.; Aboutaleb, E.; Noori, M.; Atyabi, F.; Fazeli, M.R.; Farbod, E.; Jamalifar, H.; Dinarvanda, R. Solid lipid nanoparticles of ciprofloxacin hydrochloride with enhanced antibacterial activity. J. Nanosci. Lett. 2012, 2, 21.
31. Shazly, G.A. Ciprofloxacin controlled-solid lipid nanoparticles: Characterization, in vitro release, and antibacterial activity assessment. BioMed. Res. Int. 2017, 2017, 2120734. [PubMed]
32. Sharma, A.; Sood, A.; Mehta, V.; Malairaman, U. Formulation and physicochemical evaluation of nanostructured lipid carrier for codelivery of clotrimazole and ciprofloxacin. Asian J. Pharm. Clin. Res. 2016, 9, 356–360.
33. Pandita, D.; Ahuja, A.; Velpandian, T.; Lather, V.; Dutta, T.; Khar, R.K. Characterization and in vitro assessment of paclitaxel loaded lipid nanoparticles formulated using modified solvent injection technique. Die Pharm. Int. J. Pharm. Sci. 2009, 64, 301–310.
34. Yadav, N.; Khatak, S.; Sara, U.V.S. Solid Lipid Nanoparticles. A review. Int. J. Appl. Pharm. 2013, 5, 8–18.
35. Pignatello, R.; Bucolo, C.; Ferrara, P.; Maltese, A.; Puleo, A.; Puglisi, G. Eudragit RS100 nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur. J. Pharm. Sci. 2002, 16, 53–61. [CrossRef]
36. Pignatello, R.; Bucolo, C.; Spedalieri, G.; Maltese, A.; Puglisi, G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials 2002, 23, 3247–3255. [CrossRef]
37. Bucolo, C.; Maltese, A.; Maugeri, F.; Puglisi, G.; Busà, B.; Pignatello, R. Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene. J. Pharm. Pharmacol. 2004, 56, 841–846. [CrossRef] [PubMed]
38. Pignatello, R.; Leonardi, A.; Cupri, S. Optimization and validation of a new method for the production of lipid nanoparticles for ophthalmic application. Int. J. Med. Nano Res. 2014, 1, 1–6. [CrossRef]
39. Leonardi, A.; Crascì, L.; Panico, A.; Pignatello, R. Antioxidant activity of idebenone-loaded neutral and cationic solid lipid nanoparticles. Pharm. Dev. Technol. 2015, 20, 716–723. [CrossRef] [PubMed]
40. Leonardi, A.; Bucolo, C.; Romano, G.L.; Platania, C.B.; Drago, F.; Puglisi, G.; Pignatello, R. Influence of different surfactants on the technological properties and in vivo ocular tolerability of lipid nanoparticles. Int. J. Pharm. 2014, 470, 133–140. [CrossRef] [PubMed]
41. Leonardi, A.; Bucolo, C.; Drago, F.; Salomone, S.; Pignatello, R. Cationic solid lipid nanoparticles enhance ocular hypotensive effect of melatonin in rabbit. Int. J. Pharm. 2015, 478, 180–186. [CrossRef] [PubMed]
42. Varanda, F.; Pratas de Melo, M.J.; Cacüo, A.I.; Dohrn, R.; Foteini, A.M.; Voutsas, E.; Tassios, D.; Marrucho, I.M. Solubility of Antibiotics in Different Solvents. 1. Hydrochloride Forms of Tetracycline, Moxifloxacin, and Ciprofloxacin. Ind. Eng. Chem. Res. 2006, 45, 6368–6374. [CrossRef]
43. Caço, A.I.; Varanda, F.; Pratas de Melo, M.J.; Dias, A.M.A.; Dohrn, R.; Marrucho, I.M. Solubility of Antibiotics in Different Solvents. Part II. Non-Hydrochloride Forms of Tetracycline and Ciprofloxacin. Ind. Eng. Chem. Res. 2008, 47, 8083–8089. [CrossRef]
44. EMA/CHMP/ICH/82260/2006. ICH Guideline Q3C (R6) on Impurities: Guideline for Residual Solvents Step 5; European Medicines Agency: London, UK, 6 December 2016.
45. Sobhani, Z.; Samani, S.M.; Montaseri, H.; Khezri, E. Nanoparticles of Chitosan Loaded Ciprofloxacin: Fabrication and Antimicrobial Activity. Adv. Pharm. Bull. 2017, 7, 427–432. [CrossRef] [PubMed]
46. Fawaz, F.; Bonini, F.; Maugein, J.; Lagueny, A.M. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: Pharmacokinetics and in vitro antimicrobial activity. Int. J. Pharm. 1998, 168, 255–259. [CrossRef]
47. Page-Clisson, M.E.; Pinto-Alphandary, H.; Ourevitch, M.; Andremont, A.; Couvreur, P. Development of ciprofloxacin-loaded nanoparticles: Physicochemical study of the drug carrier. J. Control. Release 1998, 56, 23–32. [CrossRef]
48. Jeong, Y.I.; Na, H.S.; Seo, D.H.; Kim, D.G.; Lee, H.C.; Jang, M.K.; Na, S.H.; Roh, S.H.; Kim, S.I.; Nah, J.W. Ciprofloxacin-encapsulated poly(dl-lactide-co-glycolide) nanoparticles and its antibacterial activity. Int. J. Pharm. 2008, 352, 317–323. [CrossRef] [PubMed]
49. Bakker-Woudenberg, I.A.J.M.; ten Kate, M.T.; Guo, L.; Working, P.; Mouton, J.W. Improved Efficacy of Ciprofloxacin Administered in Polyethylene Glycol-Coated Liposomes for Treatment of Klebsiella pneumoniae Pneumonia in Rats. Antimicrob. Agents Chemother. 2001, 45, 1487–1492. [CrossRef] [PubMed]
50. Ellbogen, M.H.; Olsen, K.M.; Gentry-Nielsen, M.J.; Preheim, L.C. Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J. Antimicrob. Chemother. 2003, 51, 83–91. [CrossRef] [PubMed]
51. Tahaa, E.I.; El-Anazi, M.H.; El-Bagory, I.M.; Bayomi, M.A. Design of liposomal colloidal systems for ocular delivery of ciprofloxacin. Saudi Pharm. J. 2014, 22, 231–239. [CrossRef] [PubMed]
52. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; 24th Informational Supplement; CLSI document M100 Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2017.
53. Furneri, P.M.; Mondello, L.; Mandalari, G.; Paolino, D.;s Dugo, P.; Garozzo, A.; Bisignano, G. In vitro antimycoplasmal activity of Citrus bergamia essential oil and its major components. Eur. J. Med. Chem. 2012, 52, 66–69. [CrossRef] [PubMed]